Researchers looked at the cases of 537 babies in England and Scotland who were admitted to hospital with severe respiratory disease.

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

The US Food and Drug Administration (FDA) has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a ...